CREBBP and B-cell non-Hodgkin lymphoma: CREBBP/EP300 mutations as a major pathogenetic mechanism shared by common forms of B-cell non-Hodgkin lymphoma (B-NHL) have direct implications for the use of drugs targeting the acetylation/deacetylation mechanism.